CD30 in T-cell lymphoma
1 EU-approved indication in T-cell lymphoma needs a CD30 result: brentuximab vedotin (2nd line).
Site
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| CD30-positive1 | ||||
Adcetris | CD30+ | Monotherapy | 2L | Cutaneous T-cell lymphoma only; After at least 1 prior systemic therapy |
4 approvals for T-cell lymphoma need no biomarker and apply whatever the result. All approvals for T-cell lymphoma
See also
Label wording1
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Brentuximab vedotin (Adcetris)
ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy (see section 5.1).